Abstract
Patients with metastatic or stage IV breast cancer have limited therapeutic options, and the mainstay of treatment remains systemic chemotherapy. Traditionally, surgery for the primary tumor has been reserved for palliation. In the current era of targeted therapies there is improved survival for patients with stage IV breast cancer. Retrospective studies demonstrate that up to 50% of patients presenting with stage IV disease who undergo breast surgery appear to have a survival advantage. It is suggested that a more aggressive and multidisciplinary approach should be considered for these selected patients. The impact of local control is greatest in the presence of effective targeted therapy support. There is a need for further study to define patient subsets that will benefit from targeted therapy support and to challenge conventional thinking about the role of surgery in stage IV breast cancer, while considering a new multimodality treatment paradigm to optimize patient outcomes. The incidence of metastatic breast disease at presentation is between 3% and 10%. Recently, encouraging reports of surgical resection of the primary tumor challenged the traditional approach of systemic therapies only in this group of patients. In this review, we aimed to discuss the hypotheses and the role of primary surgery in metastatic breast carcinoma at presentation under the guidance of published studies.
Keywords:
Metastasis, breast cancer, surgery
References
1
The American Cancer Society Cancer Facts&Figures 2010; available at www. cancer.org/docroot/STT/stt_0.asp; accessed November 14, 2010.
2
Ellis MJ. Neoadjuvant endocrine therapy for breast cancer: medical perspectives. Clin Cancer Res 2001; 7: 4388-4392.
3
Smith I, Procter M, Gelber RD, Guillaume S, Feyereisolva A, Dowsett M, Goldhirsh A. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29–36. [DOI:10.1016/S0140-6736(07)60028-2]
4
Ozmen V. Meme Hastalıkları Dernekleri etkinlikleri. Meme Sağlığı Dergisi 2010; 6: 43-44.
5
Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin, 2006;56:37-47. [DOI:10.3322/canjclin.56.1.37]
6
Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620–623.
7
Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer 2004;100: 44-52.
8
Morrow M; Goldstein L. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? J Clin Oncol 2006; 24: 2694– 2696. [DOI:10.1200/JCO.2006.05.9824.]
9
Nieto Y, Cagnoni PJ, Shpall EJ, Matthes S, Baron A, Jones RB, Bearman IS. Phase II Trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 1997; 5: 1731–1737.
10
Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wilson KE. et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-962. [DOI:10.1056/ NEJM199710023371402]
11
Campora E, Colloca G, Ratti R, Addamo G, Coccorullo G, Venturino A, Guarneri D. Docetaxel for metastatic breast cancer: two consecutive phase II trials. Anticancer Res 2008; 28: 3993-3995.
12
Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF. For the Swiss Group for Clinical Cancer Research: First isolated loco-regional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 1994; 12: 2071–2077.
13
Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696–704. [DOI:10.1002/ cncr.22041]
14
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003; 3: 537-549. [DOI:10.1016/ S1535-6108(03)00132-6]
15
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243–6249. [DOI:10.1158/1078-0432. CCR-06-0931]
16
Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 7: 456-463. [DOI:10.1093/jnci/djq029]
17
Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G. Proposal for a new model of breast cancer metastatic development. Ann Oncol 1997; 8: 1075–1080. [DOI:10.1023/A:1008263116022]
18
Gunduz N, Fisher B, Saffer AE. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Research 1979; 39: 3861-3865.
19
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–
20
[DOI:10.1016/0092-8674(94)90200-3]
21
Lang JE, Babiera GV. Locoregional resection in stage IV breast cancer: tumor biology, molecular and clinical perspectives. Surg Clin N Am 2007; 87: 527-538. [DOI:10.1016/j.suc.2007.01.001]
22
Coffey JC, Wang JH, Smith MJ, Bouchier- Hayes D, Cotter TG, Redmond H. Excisional surgery for cancer cure: therapy at a cost. Lancet Oncol 2003; 4: 760-768.
23
Braunschweiger PG, Schiffer LM, Betancourt S. Tumour cell proliferation and sequential chemotherapy after partial tumour resection in C3H/HeJ mammary tumours. Breast Cancer Res Treat 1982; 2: 323-329. [DOI:10.1007/BF01805873]
24
Hofer SO, Molema G, Hermens RA, et al. The effect of surgical wounding on tumour development. Eur J Surg Oncol 1999;25: 231-243. [DOI:10.1053/ ejso.1998.0634]
25
Weigelt B, Peterse JL, van ‘t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer, 2005; 5: 591-602. [DOI:10.1038/nrc1670]
26
Van ‘t Veer L, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536. [DOI:10.1038/415530a]
27
Sinha P, Clements VK, Miller S, Rosenberg SO. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunol Immunother 2005; 54: 1137–1142. [DOI:10.1007/s00262-005-0703-4]
28
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31. [DOI:10.1038/ nm0195-27]
29
Babiera GV, Rao R, Feng L, Meric-Bernstam F, Kuerer HM, Singletary SE, Hunt KK. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006; 13: 776–782. [DOI:10.1245/ASO.2006.03.033]
30
Schreiber H. Tumor immunology. In: Paul WE, editor. Fundamental immunology, 5. ed. Baltimore: Lippincott Williams & Wilkins, 2003, s 1557–1591.
31
Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004; 64: 2205-2211. [DOI:10.1158/0008-5472.CAN-03-2646]
32
Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. The Oncologist 2005; 10: 370–381. [DOI:10.1634/theoncologist.10-6-370]
33
Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825. [DOI:10.1097/01. sla.0000128305.90650.71]
34
Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655- 1659. [DOI:10.1056/NEJMoa003013]
35
Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002; 132: 620–627. [DOI:10.1067/ msy.2002.127544]
36
Rao R, Feng L, Kuerer HM, Singletary E, Bedrosian I, Hunt KK, Ross MI et al. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 2008; 15: 1696– 1702. [DOI:10.1245/s10434-008-9830-4]
37
Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol 2007; 14: 2187– 2194. [DOI:10.1245/s10434-007-9438-0]
38
Fields RC, Donna BJ, Trinkaus K, Zhang Q, Arthur C, Aft R, Dietz JR et. al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 2007; 14: 3345–3351. [DOI:10.1245/s10434-007-9527-0]
39
Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2007; 247: 732–738.
40
Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, Chappuis PO, Bouchardy C. Complete surgical excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006; 24: 2743–2749.
41
Neuman HB, Morrogh M, Gonen M, van Zee KJ, Morrow M, King TA. Stage IV breast cancer in the era of targeted therapy does surgery of the primary tumor matter? Cancer 2010; 1226-1233. [DOI:10.1002/cncr.24873]
42
Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol 2008 15: 3384-95. [DOI:10.1245/s10434-008-0085-x]
43
Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat 2009; 115: 7–12. [DOI:10.1007/ s10549-008-0101-7 ]
44
Hazard HW, Gorla SR, Scholtens D, Kiel K, Gradishar WJ, Khan SA. Surgical resction of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 2008; 113: 2011-2019. [DOI:10.1002/cncr.23870]
45
A Randomized trial to assess the impact of loco-regional treatment on survival of patients with metastatic breast cancer at first presentation (NCT00193778). Available at: http://clinicaltrials.gov/ct2/ show/NCT00193778.
46
Soran A, Ozbas S, Kelsey SF, Gulluoglu BM. Randomized trial comparing locoregional resection of primary tumor with no surgery in stage IV breast cancer at the presentation (protocol MF07-01): a study of Turkish Federation of the National Societies for Breast Diseases. Breast J 2009; 15: 399–403. [DOI:10.1111/j.1524- 4741.2009.00744.x]
47
Soran A; on behalf of Turkish Federation Breast Diseases Associations. The impact of primary surgery on tumor progression in metastatic breast cancer patients: Protocol MF07-01 randomized study; Interim analysis. Breast Cancer Symposium 2010, Washington DC; Proceedings. 2010:77; #93.
